PDCD1 and glioblastoma: Our clinical trial aimed at determining the tolerability and efficacy of neo-adjuvant nivolumab (anti-PD-1) combined with IL12 gene therapy in GBM showed that the combination was well tolerated, with a toxicology profile comparable to IL12 gene monotherapy [14].